Hormone receptor-positive / HER2-negative
ER and/or PR positive; not HER2-positive.
Endocrine therapy is a central treatment. Chemotherapy and additional targeted treatments depend on the clinical setting.
BREAST CANCER
Breast cancer is not one single disease. The type of cancer, its stage and its biological features all help determine the most appropriate treatment.
Many breast changes are not cancer. However, a persistent lump or other unexplained breast change should be properly evaluated rather than diagnosed by appearance or touch alone.
Breast cancer develops when abnormal cells in breast tissue grow uncontrollably. Most begin in the milk ducts or the milk-producing lobules. Breast cancer can also affect men.
Ductal carcinoma in situ (DCIS) means abnormal cells are contained within the milk ducts. It is non-invasive: the cells have not grown into the surrounding breast tissue. DCIS needs assessment and appropriate treatment because some cases can develop into invasive cancer.
Invasive breast cancer, often called invasive carcinoma, has grown beyond where it started into surrounding breast tissue. “Invasive” does not automatically mean that it has spread to distant organs.
Breast cancer is not one disease. Two people with breast cancer may require very different treatments.
Breast symptoms have many possible causes and do not automatically mean cancer. Changes that deserve assessment include:
Pain does not reliably distinguish a harmless change from cancer. Persistent inflammatory changes need prompt assessment; infection and inflammatory breast cancer can sometimes look similar.
Most breast lumps are not cancer — but a new or persistent lump should be assessed.
See also our guide to cancer warning signs.
A clinician asks about the change and relevant personal and family history, then examines the breasts and nearby lymph nodes. When appropriate, this is followed by “triple assessment”:
Age, symptoms, pregnancy or breastfeeding, previous imaging and examination findings influence which tests are used. The findings should fit together. A persistent suspicious lump may need further evaluation even if an initial scan is reassuring. Not every benign-appearing change needs a biopsy.
Mammography uses low-dose X-rays to look for breast abnormalities, including some that cannot be felt. It is used both for screening people without symptoms and for investigating symptoms or an abnormal screening result.
Ultrasound uses sound waves. It helps characterise a lump, including whether it contains fluid or is solid, and can guide a biopsy. It is particularly useful in selected situations, such as assessment in younger people, during pregnancy or as an addition to mammography. It does not automatically replace mammography.
MRI uses a magnetic field and radio waves, often with a contrast injection. It is not required for every patient. It may help in selected high-risk screening, diagnostic or staging situations, or in assessing treatment response. Additional findings sometimes need further tests.
No single imaging test is appropriate for every breast problem.
Imaging can identify a suspicious abnormality, but usually cannot establish its complete biological diagnosis. A core needle biopsy removes small cylinders of tissue, usually under local anaesthetic and often with imaging guidance. A pathologist examines the tissue to identify what it is and, if cancer is present, test relevant features.
Tissue is needed before most cancer treatment decisions because the diagnosis and receptor results can change the treatment plan. Occasionally, a different biopsy approach or repeat sampling is necessary.
A scan can show where an abnormality is. A biopsy helps determine what it actually is.
Learn more in Understanding Your Cancer Diagnosis.
The pathology report describes the tissue examined. A biopsy report and a report after surgery may contain different levels of detail. Important findings can include:
Not every report contains exactly the same information. Some biomarker results arrive as an additional report. Ask your team which findings are needed before a treatment decision.
ER = estrogen receptor.
PR = progesterone receptor.
Receptors are proteins that can receive signals from hormones. Some breast cancers use these signals to grow. Cancers with ER and/or PR expression are described as hormone-receptor-positive, and may benefit from endocrine therapy that blocks hormone signalling or reduces hormone production.
ER positivity does not automatically mean a favourable prognosis. Stage, grade, HER2, the level of receptor expression, other biological features and treatment response all matter. Low or unusual receptor results sometimes require more detailed interpretation.
HER2 is a protein involved in cell growth. Some breast cancers make too much HER2 protein or have extra copies of the HER2 gene (amplification).
HER2-positive breast cancer can be treated with HER2-directed therapies in appropriate clinical settings. HER2-positive cancers can also be hormone-receptor-positive.
You may also hear HER2-low, generally used for IHC 1+ or IHC 2+/ISH-negative disease. Lower levels of HER2 expression can have treatment implications in particular advanced-disease settings. HER2-low is not the same as conventional HER2-positive disease, and the term alone does not establish eligibility for a medicine.
Read our Cancer Biomarkers & Precision Oncology guide for more on testing and clinical interpretation.
Triple-negative breast cancer lacks ER and PR expression and does not meet the criteria for HER2-positive disease. This is a biological classification, not a description of how advanced the cancer is: triple-negative cancer can be early-stage or metastatic.
Chemotherapy remains important. Immunotherapy, selected targeted treatments and antibody–drug conjugates may also be appropriate in defined settings. Choices depend on stage, biomarkers, inherited mutations where relevant, previous treatment and clinical circumstances. Immunotherapy eligibility and the role of PD-L1 testing differ between early and metastatic disease.
ER and/or PR positive; not HER2-positive.
Endocrine therapy is a central treatment. Chemotherapy and additional targeted treatments depend on the clinical setting.
Meets validated criteria for HER2 positivity; may be ER/PR positive or negative.
HER2-directed therapy is important when indicated, often with chemotherapy. Endocrine therapy may also be relevant.
ER negative, PR negative and not HER2-positive.
Chemotherapy is important. Other treatments depend on stage, biomarkers and previous treatment.
These groups help organise treatment, but they are not the only factors determining prognosis or therapy. A subtype label does not describe an individual person’s whole situation.
Stage describes how much cancer is present and where it is located. The broad descriptions below explain anatomical extent; formal breast-cancer prognostic staging can also incorporate grade and ER/PR/HER2 results.
Stage IV is not automatically a description of someone being near the end of life. Metastatic breast cancer is generally managed as an ongoing systemic disease, with treatment to control it, relieve symptoms and help people live longer and better. Some people experience prolonged control; others have disease that progresses more quickly. Outcomes vary with tumour biology, disease burden, response and available therapies.
Your team will explain whether the stage is based on tests before treatment or findings after surgery. Stage alone does not determine prognosis.
Treatment may combine local approaches, which treat the breast and nearby areas, with systemic medicines, which work throughout the body. A multidisciplinary team considers stage, tumour biology, health and patient preferences.
Breast-conserving surgery removes the cancer with a rim of surrounding tissue. Mastectomy removes the breast. For appropriately selected early cancers, breast-conserving surgery with indicated radiotherapy offers survival comparable to mastectomy. Mastectomy is not automatically the better treatment.
Sentinel lymph-node evaluation examines selected first-draining lymph nodes when appropriate. More extensive axillary (underarm) surgery is needed only in selected circumstances. The approach depends on the findings, planned treatment and response to any preoperative therapy.
Radiotherapy uses carefully planned radiation to reduce the risk of cancer returning in the treated area. It is commonly given after breast-conserving surgery and is needed after mastectomy in selected situations. It can also help control symptoms from metastatic disease.
Chemotherapy may be given before surgery (neoadjuvant), after surgery (adjuvant), or to control metastatic cancer. It treats cancer cells throughout the body, including microscopic disease that cannot be seen on scans.
Endocrine therapy blocks hormone signals or lowers hormone levels in hormone-receptor-positive cancer. It can reduce recurrence risk after treatment for early disease and help control metastatic disease. The choice depends partly on menopausal status; ovarian suppression may be included when appropriate.
HER2-directed medicines have substantially improved outcomes in HER2-positive breast cancer. Which medicine or combination is appropriate depends on stage, previous treatment and other clinical factors. Monitoring is required, including heart assessment for some treatments.
Immunotherapy helps the immune system recognise and attack cancer. It is appropriate only in selected breast-cancer settings, including some triple-negative cancers. It can cause immune-related side effects and is not suitable for everyone.
Additional medicines may target cancer-growth pathways or DNA-repair weaknesses. Selection can depend on tumour biology, inherited mutations, acquired molecular changes, stage and prior treatment. A genetic finding does not automatically mean that a particular drug is suitable.
Explore Cancer Treatment Explained and how biomarkers guide treatment.
Neoadjuvant therapy means treatment given before surgery. Depending on the cancer, it can include chemotherapy, HER2-directed treatment, immunotherapy or selected endocrine therapy.
Possible reasons include:
This approach is particularly important in selected HER2-positive and triple-negative breast cancers. It does not mean every patient should start with medicines. Tumour size, nodes, biology and the overall clinical situation determine the sequence. Even an excellent response usually does not remove the need for planned surgery.
No. Chemotherapy is recommended when its expected benefit justifies its risks in that particular situation. Factors include:
A diagnosis of breast cancer does not automatically mean chemotherapy is required.
Examines characteristics of the cancer, often gene activity in a tissue sample. Selected assays can help estimate recurrence risk or chemotherapy benefit in defined early hormone-receptor-positive/HER2-negative settings.
These tests are not appropriate for every breast cancer, and different assays answer different questions.
Looks for inherited genetic alterations present from birth, usually using blood or saliva. A result can inform cancer risk, family assessment and sometimes treatment.
BRCA1 and BRCA2 are familiar examples; hereditary breast-cancer testing may include other genes.
A tumour recurrence-risk assay is not the same as a test for inherited cancer risk.
Neither should be confused with every form of tumour sequencing used to find treatment targets in advanced cancer. Read more about tumour and inherited testing.
Testing decisions should follow current clinical criteria and consider whether the result could affect treatment or risk management. Potential factors include:
These are examples, not a restrictive checklist. Some current guidelines recommend testing broadly, including people without an obvious family history. Genetic counselling can help with test selection, informed consent, result interpretation and implications for relatives. A variant of uncertain significance is not equivalent to a known harmful mutation.
Many early-stage breast cancers are potentially curable. Treatment is often given with that aim. An individual’s risk depends on stage, tumour biology, lymph-node involvement, treatment response and other pathological or molecular factors.
Metastatic breast cancer is generally not considered curable with current standard systemic therapy. However, many patients can experience prolonged disease control, and treatment options continue to improve. The goals and likely course should be discussed with the treating team; a single survival percentage cannot describe every person.
Breast cancer can sometimes return after initial treatment. This is called recurrence:
Risk varies substantially with the original cancer and treatment. Some recurrences happen early and others many years later. A new symptom does not automatically mean recurrence, but persistent unexplained symptoms should be discussed.
Follow-up is individualised and may include clinical review, breast imaging when appropriate, and monitoring for treatment effects. Routine PET-CT surveillance is not recommended for every symptom-free person after early breast-cancer treatment. Further scans are selected when symptoms or findings warrant investigation.
Testing people who do not have symptoms, to find cancer earlier.
Investigating a symptom or abnormal finding, regardless of whether someone is due for screening.
Screening recommendations vary with age, personal risk, family history and national guidelines. People with a high inherited risk or particular medical histories may need a different schedule and additional imaging. There is no single screening age or interval that applies to everyone in every country.
Screening has benefits and limitations, including false alarms, missed cancers and detection of some cancers that would never have caused harm. Discuss a locally appropriate plan with a healthcare professional. Do not wait for a screening invitation to have a new lump assessed.
Visit the existing Cancer Aware screening guide.
Being familiar with what is normal for your breasts can help you notice a persistent unexplained change. There is no need to diagnose a lump yourself or rely on a particular self-examination ritual. Seek assessment for a new or persistent change, even after a recent normal screening test.
Breast awareness complements screening. It does not replace it.
Fact: Pain alone cannot reliably distinguish benign from malignant disease.
Fact: Modern appropriately performed biopsy is a standard part of cancer diagnosis and does not ordinarily cause cancer to spread through the body.
Fact: Many breast lumps are benign, but persistent or suspicious changes should be evaluated.
Fact: For appropriately selected early breast cancers, breast-conserving therapy can provide excellent cancer outcomes. The whole treatment plan, including indicated radiotherapy, matters.
Fact: Treatment depends on stage, tumour biology and other clinical factors.
Explore more cancer myths and facts.
CANCER AWARE · YOUR APPOINTMENT CHECKLIST
Most breast changes are not caused by cancer. However, a new or persistent unexplained change deserves proper medical assessment.
Arrange an assessment for an unexplained breast or armpit lump, a persistent nipple change or unusual discharge. Rapidly developing redness or swelling, especially with fever or feeling unwell, needs prompt assessment. These changes may have treatable causes other than cancer.
This guide summarises and paraphrases established breast-cancer education and guidance. These resources provide further context; they do not establish an individual person’s eligibility for a test or treatment.
Recommendations evolve. Individual decisions require clinical assessment and current cancer-specific guidance, taking local approvals and availability into account. The USPSTF resource describes United States screening policy, not a universal schedule. Reference to these organisations does not imply endorsement or affiliation.
Dr Hakeem Ansar Hussain
Medical Oncologist
Last medically reviewed:
The information on Cancer Aware is provided for general education and awareness only. It is not a substitute for consultation, diagnosis or treatment by a qualified healthcare professional. If you have persistent, worsening or concerning symptoms, please seek medical advice.